It is argued that resistance to targeted therapies, endocrine therapies, and PARP inhibitors should not be treated as a problem separate from immunotherapy resistance, but rather, these resistant states often converge on the same three axes that govern immunotherapy resistance (immune visibility, access, and effector f...
Ha-Eun Jeong, Heesun Choi, W. Lim et al.· Journal of Experimental &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.